Lyell Immunopharma Q2 net loss narrows to $45.8M; LYL797 shows 40% ORR in TNBC

Lyell Immunopharma, Inc.

2024-Q2 EPS reported -$0.42 revenue$16,000

Net loss of $45.8M ($63.9M in Q2 2023); non-GAAP net loss $39.1M ($45.6M).
Cash, equivalents and marketable securities $491.1M as of June 30, 2024, funding operations into 2027.
LYL797 Phase 1: 40% objective response rate and 60% clinical benefit rate at 150x10^6 cells in relapsed/refractory TNBC.
FDA cleared IND for LYL119 (next-gen ROR1 CAR T); Phase 1 to start in ROR1+ ovarian/endometrial cancers.
R&D expenses decreased to $40.3M; G&A expenses to $12.3M, driven by November 2023 workforce reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.